scholarly journals Investigating the response of paediatric leukaemia‐propagating cells to BCL‐2 inhibitors

2020 ◽  
Author(s):  
Paraskevi Diamanti ◽  
Benjamin C. Ede ◽  
Phoebe EI Dace ◽  
William J. Barendt ◽  
Charlotte V. Cox ◽  
...  
Keyword(s):  
Paediatric Leukaemia

scholarly journals PO-405 Repositioning existing drugs as novel therapeutics for high-risk paediatric leukaemia

2018 ◽  
Author(s):  
M Karsa ◽  
T Failes ◽  
GM Arndt ◽  
UR Kees ◽  
M Haber ◽  
...  
Keyword(s):  
High Risk ◽  
Novel Therapeutics ◽  
Paediatric Leukaemia

The challenge of obesity in paediatric leukaemia treatment: it is not just size that matters

2014 ◽  
Vol 100 (1) ◽  
pp. 101-105 ◽  
Author(s):  
Jaszianne Tolbert ◽  
Gregory L Kearns
Keyword(s):  
Drug Disposition ◽  
Lymphocytic Leukaemia ◽  
Genetic Constitution ◽  
Acute Lymphocytic Leukaemia ◽  
Dose Individualisation ◽  
Maintenance Of Remission ◽  
Paediatric Leukaemia ◽  
Cure Rates ◽  
The Impact ◽  
Made In

In the last two decades, tremendous advances have been made in the treatment of acute lymphocytic leukaemia (ALL) in children with 5 year ‘cure’ rates in excess of 90%. The maintenance of remission is due, in part, to individualisation of therapy which must consider age, body size, genetic constitution and the impact of disease on drug disposition and action. This review, focused on treatment of ALL and one of the therapeutic mainstays, 6-mercaptopurine, illustrates the importance of obesity as a modulating factor in dose individualisation.

scholarly journals Paediatric leukaemia DNA methylation profiling using MBD enrichment and SOLiD sequencing on archival bone marrow smears

GigaScience ◽  
2015 ◽  
Vol 4 (1) ◽  
Author(s):  
Nicholas CL Wong ◽  
Gavin D Meredith ◽  
George Marnellos ◽  
Miroslav Dudas ◽  
Mandy Parkinson-Bates ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Bone Marrow ◽  
Dna Methylation Profiling ◽  
Paediatric Leukaemia ◽  
Methylation Profiling

scholarly journals Folate metabolism: a re-emerging therapeutic target in haematological cancers

Leukemia ◽  
2021 ◽  
Author(s):  
Martha M. Zarou ◽  
Alexei Vazquez ◽  
G. Vignir Helgason
Keyword(s):  
Side Effects ◽  
De Novo ◽  
Therapeutic Strategies ◽  
Chemotherapeutic Agents ◽  
Cellular Level ◽  
Folate Metabolism ◽  
Methionine Cycle ◽  
Paediatric Leukaemia ◽  
Thymidylate Synthesis ◽  
New Chemotherapeutic Agents

AbstractFolate-mediated one carbon (1C) metabolism supports a series of processes that are essential for the cell. Through a number of interlinked reactions happening in the cytosol and mitochondria of the cell, folate metabolism contributes to de novo purine and thymidylate synthesis, to the methionine cycle and redox defence. Targeting the folate metabolism gave rise to modern chemotherapy, through the introduction of antifolates to treat paediatric leukaemia. Since then, antifolates, such as methotrexate and pralatrexate have been used to treat a series of blood cancers in clinic. However, traditional antifolates have many deleterious side effects in normal proliferating tissue, highlighting the urgent need for novel strategies to more selectively target 1C metabolism. Notably, mitochondrial 1C enzymes have been shown to be significantly upregulated in various cancers, making them attractive targets for the development of new chemotherapeutic agents. In this article, we present a detailed overview of folate-mediated 1C metabolism, its importance on cellular level and discuss how targeting folate metabolism has been exploited in blood cancers. Additionally, we explore possible therapeutic strategies that could overcome the limitations of traditional antifolates.

scholarly journals Adenovirus detection in Guthrie cards from paediatric leukaemia cases and controls

2008 ◽  
Vol 99 (10) ◽  
pp. 1668-1672 ◽  
Author(s):  
G M Vasconcelos ◽  
M Kang ◽  
M S Pombo-de-Oliveira ◽  
J D Schiffman ◽  
F Lorey ◽  
...  
Keyword(s):  
Paediatric Leukaemia ◽  
Guthrie Cards
Sign in / Sign up

Export Citation Format

Share Document